Written by
Mustafa Çelik
Mustafa Çelik Liv Hospital Content Team
Medically reviewed by

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
...
Views
Read Time
...
views
Read Time
How Fast Does Acute Myeloid Leukaemia (AML) Develop and How Deadly Is It?
How Fast Does Acute Myeloid Leukaemia (AML) Develop and How Deadly Is It? 2

At Liv Hospital, we know how critical quick and correct diagnosis is for aggressive cancers like Acute Myeloid Leukaemia (AML). AML starts in the bone marrow and quickly moves into the blood. It can spread to other parts of the body, like the lymph nodes, liver, spleen, central nervous system, and testicles in men.

The disease is marked by the fast growth of abnormal white blood cells. These cells build up in the bone marrow and block the production of normal blood cells. We see AML as an aggressive leukemia because it starts suddenly and grows fast.

We are working on treatments like Actimab-A for relapsed and refractory AML patients. When used with chemotherapy CLAG-M, it shows promise. We are dedicated to giving the latest, respected care to our patients.

Key Takeaways

  • AML is a rapidly progressing cancer with high mortality rates.
  • The disease originates in the bone marrow and can spread to other parts of the body.
  • Abnormal white blood cells accumulate in the bone marrow, interfering with normal blood cell production.
  • Timely diagnosis is critical for effective treatment.
  • Liv Hospital is committed to providing world-class care for international patients.

Understanding Acute Myeloid Leukaemia (AML)

Serious doctor patient and holding hands in consultation for bad news canc
How Fast Does Acute Myeloid Leukaemia (AML) Develop and How Deadly Is It? 3

AML is a group of diseases where myeloid blasts grow in the bone marrow and blood. Knowing this is key for diagnosis and treatment.

What Is AML? Defining the Disease

AML is a cancer that starts in the bone marrow and quickly spreads to the blood. It can also reach other parts like the lymph nodes, liver, and spleen. The disease is marked by fast-growing, abnormal white blood cells that block the production of healthy blood cells.

“The clonal expansion of myeloid blasts is a hallmark of AML, leading to a complex clinical presentation that requires prompt and precise diagnosis,” says a leading hematologist.

AML in Medical Terms: Key Characteristics

Medically, AML falls under myeloblastic leukemia. It happens when abnormal myeloid white blood cells grow uncontrollably. These cells can’t fight infections well, causing issues like anemia, infections, and bleeding problems.

The World Health Organization (WHO) classification is key for AML. It looks at genetic, morphological, and clinical features. This helps in understanding the disease and planning treatment.

Classification of AML Subtypes

AML classification has changed over time. Now, we have different subtypes based on genetic traits and cell surface proteins. Knowing these subtypes helps in choosing the right treatment.

AML is not just one disease but a group with various traits and treatment responses. Finding specific genetic mutations and cytogenetic abnormalities is vital for managing AML.

Acute Leukaemia: The Aggressive Nature of AML

Doctor speaking with cheerful young patient
How Fast Does Acute Myeloid Leukaemia (AML) Develop and How Deadly Is It? 4

“Acute” in Acute Myeloid Leukaemia means the disease hits fast and hard. AML makes lots of immature white blood cells that don’t work right.

We will look at why AML is so aggressive and how it affects patients.

What Makes AML an Acute Form of Leukemia

AML starts suddenly and grows fast. It’s different from chronic leukemias that grow slowly. AML quickly fills the bone marrow and blood with bad cells.

AML’s quick nature is due to:

  • Fast growth of bad cells in the bone marrow and blood
  • Symptoms come on fast, causing anemia, infections, and bleeding
  • It needs quick treatment to avoid serious problems

Myeloblastic Leukaemia Development

AML starts with changes in genes and environment. DNA changes help find AML early and accurately. These changes make myeloid cells turn bad, leading to AML’s hallmark cells.

The Impact of Leukaemia White Blood Cells

The white blood cells in AML don’t fight infections well. They take over the bone marrow, causing anemia, low white blood cells, and low platelets. These bad cells also weaken the immune system, making patients more likely to get sick.

Knowing how these white blood cells work is key to better treatments and outcomes.

How Fast Does AML Develop? The Timeline of Disease Progression

Knowing how fast AML develops is key for quick medical help. AML is aggressive and can grow quickly.

We’ll look at AML’s development timeline, from first cell changes to when symptoms appear. We’ll also talk about what makes the disease progress faster.

From First Cellular Changes to Clinical Manifestation

AML starts with genetic changes in myeloid cells, causing abnormal cell growth. This can take weeks to months.

Initial cellular changes might not show symptoms right away. But as more leukemic cells build up, symptoms start to show.

Rapid Progression in Untreated Cases

In cases without treatment, AML can grow fast, sometimes in days or weeks. It can cause serious problems like infections, anemia, and bleeding issues.

The aggressive nature of AML means we need to find and treat it quickly to help patients.

Factors Affecting Development Speed

Many things can change how fast AML grows, like genetic mutations, chromosomal problems, and the patient’s health.

FactorImpact on AML Development
Genetic MutationsSome mutations can make AML grow faster.
Chromosomal AbnormalitiesThings like translocations can make the disease more aggressive.
Patient’s Overall HealthBeing sick before getting AML can affect how fast it grows.

Recent studies show the CLOCK gene’s role in cancer, like glioblastoma. Its effect on AML is being studied, but knowing about it can help us understand AML better.

Recognizing AML: Symptoms and Warning Signs

AML symptoms can be tricky to spot early. Knowing them can help get medical help fast. We’ll look at the early signs and more serious symptoms that might mean AML is present.

Early Symptoms Often Overlooked

In the beginning, AML symptoms can seem like other health issues. This makes it hard to figure out what’s wrong. Early signs include:

  • Fatigue: Feeling very tired or weak without a clear reason.
  • Weight Loss: Losing weight without trying can be a sign of AML.
  • Recurrent Infections: Getting sick a lot might mean your immune system is weak.

These signs are often thought to be minor issues, causing delays in finding out what’s really wrong.

Advanced Symptoms as Disease Progresses

As AML gets worse, symptoms get more serious. These include:

  • Bleeding Gums: Unexplained bleeding or bruising, like bleeding gums.
  • Petechiae: Small red or purple spots on the skin from bleeding under the skin.
  • Anemia: Not having enough red blood cells, leading to tiredness and weakness.

These signs show the disease is getting worse and need quick medical care.

When to Seek Medical Attention

If you or someone you know has these symptoms, get medical help right away. Early treatment can greatly improve AML outcomes.

It’s key to know the signs of AML and get medical help for unusual or lasting symptoms. Quick action can greatly improve AML treatment and management.

Diagnosing AML: Tests and Procedures

Diagnosing AML is a detailed process. It involves blood tests, bone marrow checks, and genetic analysis. Accurate diagnosis is key for the right treatment and understanding the patient’s future.

Initial Blood Tests and Complete Blood Count

The first step is initial blood tests, including a Complete Blood Count (CBC). A CBC looks at different blood cells. In AML, it shows abnormal counts, like too many white blood cells or blasts.

“The presence of blasts in the peripheral blood is a critical indicator of AML,” say hematologists. These early signs guide us to more tests.

Bone Marrow Biopsy and Aspiration

A bone marrow biopsy and aspiration are key for AML diagnosis. This procedure takes a bone marrow sample, usually from the hip. It checks for myeloid blasts, the cells that show AML.

AML is confirmed if at least 20% of the cells in the bone marrow are myeloid blasts. This, along with genetic and morphological features, helps tell AML apart from other leukemias.

Genetic Testing and Cytogenetic Analysis

Genetic testing and cytogenetic analysis are vital for AML diagnosis and understanding its outlook. These tests look at the leukemia cells’ genetic material for specific mutations or chromosomal changes.

  • Cytogenetic analysis helps in risk stratification by identifying genetic changes that affect the prognosis.
  • Molecular genetic testing can detect specific mutations that may influence treatment decisions.

Knowing AML’s genetic makeup is key for personalized treatment. As research grows, genetic testing’s role in AML diagnosis keeps evolving.

“Dysregulation of DNA methylation is a hallmark of AML, and understanding how DNA methylation marks interact across the genome is critical for developing targeted therapies,” recent studies say. We’re exploring how these genetic insights can better patient outcomes.

Is AML Rare? Epidemiology and Demographics

AML is rare but serious, mainly affecting older adults and those with certain risk factors. We’ll look into AML’s spread, how often it happens, and who it affects. This will help us understand this complex disease better.

Prevalence and Incidence Rates

AML is rare, with its occurrence varying worldwide. It’s a big part of leukemia cases in adults. Most AML cases happen in people over 60.

Here are some important numbers:

Age GroupIncidence Rate per 100,000
20-290.6
30-391.1
40-492.3
50-594.5
60+12.6

The table shows AML’s rate goes up with age. This means we need to focus more on screening older adults.

Age, Gender, and Demographic Patterns

AML hits different groups in different ways. It’s more common in men than women, and varies by ethnicity. Knowing this helps us create better health plans.

“The epidemiology of AML is complex, with multiple factors influencing its incidence and prevalence. Further research is needed to elucidate the underlying causes of these demographic variations.”

Known Risk Factors for Developing AML

Several things can raise your risk for AML. Exposure to chemicals like benzene and radiation are big ones. So is past chemotherapy, like with topoisomerase II inhibitors. People with these exposures should get checked for AML regularly.

What Is the Deadliest Type of Leukemia? AML’s Mortality Profile

AML is a serious type of leukemia with a high death rate. It grows quickly and needs fast treatment to survive.

AML as One of the Worst Leukemia Types

AML is very deadly because it spreads fast and is fatal if not treated. It causes severe problems and has a bad outlook. Studies show AML kills many, mostly older people and those with genetic issues .

Survival Statistics and Prognosis Factors

AML survival rates depend on age, genetics, and treatment response. It has a low five-year survival rate compared to other leukemias. Health, genetics, and treatment response are key to survival.

Age Group5-Year Survival Rate
20-39 years40%
40-59 years30%
60+ years10%

Untreated AML: The Fatal Timeline

Without treatment, AML quickly becomes fatal. The time from diagnosis to death varies but is often short. AML’s aggressive nature and impact on blood cells make early treatment vital.

In summary, AML’s high death rate is a major concern. Knowing survival rates and factors helps patients and doctors choose the best treatments.

Comparing AML to Other Leukemia Types

 Leukemia is a blood and bone marrow cancer, divided into subtypes based on cell type and disease speed. Acute Myeloid Leukemia (AML) is a fast-progressing subtype that affects myeloid cells.

AML vs. Acute Lymphoblastic Leukemia (ALL)

AML and ALL are both fast-moving leukemias. But they affect different blood cells. AML impacts myeloid cells, which turn into red blood cells, platelets, and some white blood cells. ALL, on the other hand, affects lymphoblasts, turning into lymphocytes, a different white blood cell type.

Acute Myeloid vs. Chronic Myeloid Leukemia

AML and Chronic Myeloid Leukemia (CML) differ in how fast they progress. AML is an acute leukemia that needs quick treatment. CML, a chronic leukemia, progresses slowly, sometimes turning aggressive later.

CML’s slow pace allows for treatments like targeted therapies, improving patient outcomes.

Distinguishing AML from Acute Myeloid Lymphoma

AML and Acute Myeloid Lymphoma are different in their origins and symptoms. AML affects the bone marrow and blood, while lymphoma targets lymphoid tissues. Though they share symptoms like fatigue and weight loss, their treatments differ.

In summary, understanding the differences between AML and other leukemias is key for accurate diagnosis and treatment. Recognizing each subtype’s unique traits helps healthcare providers tailor care for patients.

Treatment Approaches for AML

When we look at AML treatment, we see a mix of old and new methods. Each patient needs a plan that fits their unique situation and health history.

Standard Treatment Protocols

For AML, chemotherapy is often the first choice. It aims to kill leukemia cells in the bone marrow. We use different drugs together to get the best results.

Sometimes, targeted therapy is used. This type of treatment attacks specific genes or proteins in leukemia cells.

Emerging Therapies and Clinical Trials

New treatments for AML are coming, like targeted agents and immunotherapies. For example, Actimab-A is moving to a Phase 2/3 trial. This shows a hopeful future for AML treatment.

Clinical trials are key in testing these new treatments. They help find out if these therapies are safe and work well. This way, patients can try new treatments that might not be available yet.

Factors Affecting Treatment Success

How well AML treatment works depends on several things. These include the patient’s age, the leukemia’s genetic makeup, and any other health issues. Knowing these details helps us create a good treatment plan.

We also think about the patient’s overall health and how well they can handle tough treatments. This helps us choose the best treatment for them.

Conclusion: Living with an AML Diagnosis

Getting an Acute Myeloid Leukaemia (AML) diagnosis can feel scary. But knowing about the disease and treatment choices is key to managing care. AML, or acute myeloid lymphoma, is a fast-moving leukemia that needs quick action.

Scientists are studying how AML works, looking at DNA changes and how proteins are modified. This research is important for finding new treatments and helping patients. If you have AML, it’s important to know how serious it is. In some cases, it can be very dangerous if not treated, even life-threatening in just a week.

Dealing with AML means working with many healthcare experts. You’ll need hematologists, oncologists, and others who support your care. Knowing about AML helps patients in the UK and around the world understand their treatment better.

What is Acute Myeloid Leukaemia (AML)?

AML is a cancer that starts in the bone marrow and quickly spreads to the blood. It’s caused by abnormal white blood cells growing fast. These cells fill the bone marrow, stopping normal blood cells from being made.

How fast does AML develop?

AML can grow quickly, sometimes in just days or weeks. This speed depends on genetic changes, specific chromosomal issues, and the person’s health.

Is AML a rare disease?

Yes, AML is rare. But it’s more common with age, mainly affecting people over 60.

What are the common symptoms of AML?

Symptoms of AML can be vague and include tiredness, weight loss, and frequent infections. As it gets worse, symptoms like bleeding gums and anemia may appear.

How is AML diagnosed?

Doctors diagnose AML by finding at least 20% myeloid blasts in the bone marrow or blood. They use blood tests, bone marrow biopsies, and genetic tests to confirm.

What is the prognosis for AML?

AML’s outlook varies. It depends on age, genetic traits, and how well the treatment works.

How does AML compare to other types of leukemia?

AML is different from Acute Lymphoblastic Leukemia (ALL) because it affects different cells. Chronic Myeloid Leukemia (CML) grows slower than AML.

What are the treatment approaches for AML?

Treatments for AML include chemotherapy, new targeted therapies, and clinical trials. Success depends on age, genetic makeup, and health status.

Can leukemia kill you in a week?

Yes, AML can be very aggressive and deadly if not treated quickly. But, with fast treatment, the outlook can improve.

What is myeloblastic leukaemia?

Myeloblastic leukaemia is another name for AML. It’s when myeloid blasts build up in the bone marrow and blood.

What is the deadliest type of leukemia?

AML is one of the most dangerous leukemias because it grows fast and is aggressive.

What does AML stand for in medical terms?

AML stands for Acute Myeloid Leukaemia. It’s a cancer that affects the blood and bone marrow.

Reference

Wikipedia. Acute myeloid leukemia. https://en.wikipedia.org/wiki/Acute_myeloid_leukemia

Blood Cancer United. Stages of Leukemia: Understanding Classification and Progression. https://bloodcancerunited.org/resources/blog/stages-leukemia-understanding-classification-and-progression

NCBI. Research. https://www.ncbi.nlm.nih.gov/books/NBK560490/

NCBI. Research. https://www.ncbi.nlm.nih.gov/books/NBK507875/

i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Evrim Duman Radiation Oncology

Assoc. Prof. MD. Evrim Duman

Liv Hospital Ulus
Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology

Asst. Prof. MD. Meltem Topalgökçeli Selam

Liv Hospital Ulus
Prof. MD. Duygu Derin Medical Oncology

Prof. MD. Duygu Derin

Liv Hospital Ulus
Prof. MD. Emre Merdan Fayda Radiation Oncology

Prof. MD. Emre Merdan Fayda

Liv Hospital Ulus
Prof. MD. Mehmet Hilmi Doğu Hematology

Prof. MD. Mehmet Hilmi Doğu

Liv Hospital Ulus
Liv Hospital Bahçeşehir
Prof. MD. Meral Günaldı Medical Oncology

Prof. MD. Meral Günaldı

Liv Hospital Ulus
Assoc. Prof. MD. Murat Ayhan Medical Oncology

Assoc. Prof. MD. Murat Ayhan

Liv Hospital Vadistanbul
Prof. MD.  Itır Şirinoğlu Demiriz Hematology

Prof. MD. Itır Şirinoğlu Demiriz

Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Prof. MD. Tülin Tıraje Celkan

Liv Hospital Vadistanbul
Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology

Assoc. Prof. MD. Erkan Kayıkçıoğlu

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Mine Dağgez Gynecological Oncology

Assoc. Prof. MD. Mine Dağgez

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ozan Balakan Medical Oncology

Assoc. Prof. MD. Ozan Balakan

Liv Hospital Bahçeşehir
MD. Taylan Bükülmez Radiation Oncology

MD. Taylan Bükülmez

Liv Hospital Bahçeşehir
Op. MD. Alp Koray Kinter Gynecological Oncology

Op. MD. Alp Koray Kinter

Liv Hospital Bahçeşehir
Prof. MD. Nuri Faruk Aykan Medical Oncology

Prof. MD. Nuri Faruk Aykan

Liv Hospital Bahçeşehir
Spec. MD. Özlem Doğan Medical Oncology

Spec. MD. Özlem Doğan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Emir Çelik Medical Oncology

Assoc. Prof. MD. Emir Çelik

Liv Hospital Topkapı
Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology

Assoc. Prof. MD. Muhammed Mustafa Atcı

Liv Hospital Topkapı
Prof. MD. İrfan Çiçin Medical Oncology

Prof. MD. İrfan Çiçin

Liv Hospital Topkapı
Assoc. Prof. MD.  Ramazan Öcal Hematology

Assoc. Prof. MD. Ramazan Öcal

Liv Hospital Ankara
Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology

Assoc. Prof. MD. Nazlı Topfedaisi Özkan

Liv Hospital Ankara
Prof. MD. Fikret Arpacı Medical Oncology

Prof. MD. Fikret Arpacı

Liv Hospital Ankara
Prof. MD. Gökhan Erdem Medical Oncology

Prof. MD. Gökhan Erdem

Liv Hospital Ankara
Prof. MD. Meral Beksaç Hematology

Prof. MD. Meral Beksaç

Liv Hospital Ankara
Prof. MD. Oral Nevruz Hematology

Prof. MD. Oral Nevruz

Liv Hospital Ankara
Prof. MD. Saadettin Kılıçkap Medical Oncology

Prof. MD. Saadettin Kılıçkap

Liv Hospital Ankara
Prof. MD. Sadık Muallaoğlu Medical Oncology

Prof. MD. Sadık Muallaoğlu

Liv Hospital Ankara
Spec. MD. Ender Kalacı Medical Oncology

Spec. MD. Ender Kalacı

Liv Hospital Ankara
Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Assoc. Prof. MD. Fadime Ersoy Dursun

Liv Hospital Gaziantep
Prof. MD. Fatih Teker Medical Oncology

Prof. MD. Fatih Teker

Liv Hospital Gaziantep
Spec. MD. ELXAN MEMMEDOV Medical Oncology

Spec. MD. ELXAN MEMMEDOV

Liv Bona Dea Hospital Bakü
Spec. MD. Ceyda Aslan Hematology

Spec. MD. Ceyda Aslan

Spec. MD. Elkhan Mammadov Medical Oncology

Spec. MD. Elkhan Mammadov

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Elmir İsrafilov

Spec. MD. Minure Abışova Eliyeva Hematology

Spec. MD. Minure Abışova Eliyeva

Spec. MD. Natavan Azizova Medical Oncology

Spec. MD. Natavan Azizova

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 174 26 75